RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

Add to Collection
2021 Jun RCTs Fist_Author_Year_PM

Full Author : ['McCrimmon, Rory J', 'Al Sifri, Saud', 'Emral, Rifat', 'Mohan, Viswanathan', 'Sauque-Reyna, Leobardo', 'Trescoli, Carlos', 'Lalic, Nebojsa', 'Alvarez, Agustina', 'Demil, Nacima', 'Coudert, Mathieu', 'Shaunik, Alka', 'Bonnemaire, Mireille', 'Rosenstock, Julio']
Journal Title : Diabetes, obesity & metabolism
Chapter : Section3
Journal Year : 2021
Cited by : Not Available

AIM: Premix insulin is commonly used in some regions of the world, despite the higher risk of hypoglycaemia and weight gain compared with basal insulin, based on the premise that it offers a simplified insulin regimen. iGlarLixi is a once-daily titratable.....

Keywords : ["basal insulintreate type diabetes design", "solimix randomize control trial", "iglarlixi versus premix biasp", "baseline characteristic", "advance therapy"]